{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_018659.4:c.6071T>A",
          "cDNA Change": {
            "transcript": "NM_018659.4",
            "ref": "T",
            "alt": "A",
            "position": "6071"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "c.6071T>A (p.I2020T)"
        },
        {
          "HGVS": "NM_018659.4:c.6057G>S",
          "cDNA Change": {
            "transcript": "NM_018659.4",
            "ref": "G",
            "alt": "S",
            "position": "6057"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "c.6057G>S (p.G2019S)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO_0003847"
  },
  "Experiment Method": [
    {
      "Assay Method": "Binding Assays and Kinase Activity Assays",
      "Material used": {
        "Material Source": "In vitro (recombinant protein)",
        "Material Name": "Recombinant LRRK2 proteins",
        "Description": "The experiments were conducted using recombinant LRRK2 proteins."
      },
      "Readout type": [
        "Quantitative"
      ],
      "Readout description": [
        {
          "Variant": "NM_018659.4:c.6071T>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "partial loss-of-function",
          "Result Description": "Protein showed reduced ATP binding affinity."
        },
        {
          "Variant": "NM_018659.4:c.6057G>S",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Protein exhibited increased sensitivity to kinase inhibitors."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "No information provided."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "No information provided."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "No information provided."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "No information provided."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal ATP binding affinity and kinase activity as per wild-type measurements.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significantly reduced or altered ATP binding affinity and kinase activity compared to wild-type.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes",
        "Description": "Binding assays and kinase activity assays are standard methods for studying enzyme function in Parkinson's disease research."
      }
    }
  ]
}